Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China · Delayed Price · Currency is CNY 21.07
-0.33 (-1.54%)
At close: Jan 30, 2026
SHE:301246 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 |
Net Income | 14.22 | 51.47 | 87.17 | 434.8 | 493.85 | 257.18 |
Depreciation & Amortization | 178.6 | 178.6 | 156.88 | 89.8 | 80.36 | 74.37 |
Other Amortization | 3.39 | 3.39 | 4.44 | 6.14 | 5.52 | 3.11 |
Loss (Gain) From Sale of Assets | -0.53 | -0.53 | -0.57 | -14.44 | 0 | -1.88 |
Asset Writedown & Restructuring Costs | 0.27 | 0.27 | - | 1.97 | 7.88 | 9.89 |
Loss (Gain) From Sale of Investments | -5.24 | -5.24 | -20.99 | -169.14 | -190.23 | 15.15 |
Provision & Write-off of Bad Debts | 0.51 | 0.51 | -2.55 | 4.29 | 1.03 | 0.07 |
Other Operating Activities | -91.47 | 47.63 | 46.45 | 38.7 | 7.45 | 21.13 |
Change in Accounts Receivable | - | - | - | -494.66 | -289.98 | -155.24 |
Change in Inventory | -74.75 | -74.75 | 135.06 | -178.49 | -81.72 | -63.5 |
Change in Accounts Payable | -226.16 | -226.16 | -374.53 | 498.4 | 165.33 | -18.51 |
Change in Other Net Operating Assets | 8.62 | 8.62 | - | - | - | - |
Operating Cash Flow | -192.16 | -15.81 | 35.25 | 214.99 | 196.1 | 142.39 |
Operating Cash Flow Growth | - | - | -83.60% | 9.63% | 37.71% | -39.72% |
Capital Expenditures | -142.52 | -160.2 | -474.64 | -507.09 | -259.01 | -56.86 |
Sale of Property, Plant & Equipment | 3.1 | 1.36 | 1.14 | 104.26 | 1.33 | 152.75 |
Cash Acquisitions | -3.2 | -3.2 | - | - | - | - |
Investment in Securities | -655.66 | 575.55 | -1,596 | 33 | 0.01 | 2.87 |
Other Investing Activities | -84.07 | - | - | - | - | 0.79 |
Investing Cash Flow | -882.34 | 413.51 | -2,069 | -369.83 | -257.67 | 99.55 |
Long-Term Debt Issued | - | 51.14 | 21.25 | 494.5 | 110 | 199.98 |
Total Debt Issued | 443.08 | 51.14 | 21.25 | 494.5 | 110 | 199.98 |
Long-Term Debt Repaid | - | -66.9 | -98.28 | -55.07 | -188.85 | -354.46 |
Total Debt Repaid | -164.4 | -66.9 | -98.28 | -55.07 | -188.85 | -354.46 |
Net Debt Issued (Repaid) | 278.67 | -15.76 | -77.02 | 439.43 | -78.85 | -154.48 |
Issuance of Common Stock | - | - | 2,196 | - | - | - |
Repurchase of Common Stock | -32.8 | -32.8 | - | - | - | - |
Common Dividends Paid | -25.51 | -30.86 | -53.8 | -14.97 | -2.22 | -8.74 |
Dividends Paid | -25.51 | -30.86 | -53.8 | -14.97 | -2.22 | -8.74 |
Other Financing Activities | 112.07 | -97.48 | 88.07 | -134.32 | 15.27 | 8.68 |
Financing Cash Flow | 332.43 | -176.9 | 2,153 | 290.13 | -65.79 | -154.54 |
Foreign Exchange Rate Adjustments | 2.39 | 4.98 | 0.57 | 5.65 | -1.13 | -7.57 |
Net Cash Flow | -739.68 | 225.78 | 119.68 | 140.94 | -128.49 | 79.83 |
Free Cash Flow | -334.68 | -176.01 | -439.39 | -292.1 | -62.92 | 85.53 |
Free Cash Flow Growth | - | - | - | - | - | -36.51% |
Free Cash Flow Margin | -18.96% | -9.94% | -21.38% | -14.15% | -3.99% | 6.57% |
Free Cash Flow Per Share | -0.85 | -0.44 | -1.13 | -0.83 | -0.18 | 0.24 |
Cash Income Tax Paid | - | -19.15 | 67.14 | 45.74 | 89.49 | 87.38 |
Levered Free Cash Flow | -637.93 | 187.98 | -511.52 | 120.97 | 53.49 | 213.49 |
Unlevered Free Cash Flow | -631.7 | 195.48 | -503.15 | 123.1 | 54.98 | 223.15 |
Change in Working Capital | -291.91 | -291.91 | -235.58 | -177.13 | -209.77 | -236.63 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.